| Identification of Patient Subgroups Demonstrating Longer Progression-Free Survival (PFS) Benefit with Bortezomib-Rituximab Versus Rituximab in Patients with Relapsed or Refractory Follicular Lymphoma (FL): Biomarker Analyses of the Phase 3 LYM3001 Study | |
| Coiffier, Bertrand; Li, Weimin; Henitz, Erin D.; Karkera, J. D.; Favis, Reyna; Gaffney, Dana; Shapiro, Alice; Theocharous, Panteli; Elsayed, Yusri A.; van de Velde, Helgi | |
| 2011 | |
| 卷号 | 118 |
| 期号 | 21 |
| 会议录 | BLOOD
 |
| 语种 | 英语 |
| URL标识 | 查看原文 |
| ISSN号 | 0006-4971 |
| 内容类型 | 会议论文 |
| URI标识 | http://www.corc.org.cn/handle/1471x/4921567 |
| 专题 | 复旦大学上海医学院 |
| 推荐引用方式 GB/T 7714 | Coiffier, Bertrand,Li, Weimin,Henitz, Erin D.,et al. Identification of Patient Subgroups Demonstrating Longer Progression-Free Survival (PFS) Benefit with Bortezomib-Rituximab Versus Rituximab in Patients with Relapsed or Refractory Follicular Lymphoma (FL): Biomarker Analyses of the Phase 3 LYM3001 Study[C]. 见:. |
| 个性服务 |
| 查看访问统计 |
| 相关权益政策 |
| 暂无数据 |
| 收藏/分享 |
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。
修改评论